sorafenib has been researched along with warfarin in 9 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (warfarin) | Trials (warfarin) | Recent Studies (post-2010) (warfarin) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 36,573 | 2,143 | 14,728 |
Protein | Taxonomy | sorafenib (IC50) | warfarin (IC50) |
---|---|---|---|
Vitamin K epoxide reductase complex subunit 1 | Homo sapiens (human) | 0.0088 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (11.11) | 29.6817 |
2010's | 4 (44.44) | 24.3611 |
2020's | 4 (44.44) | 2.80 |
Authors | Studies |
---|---|
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Montalvo, RO; Moretti, LV | 1 |
Hara, F; Hirano, N; Iida, K; Ishii, K; Kikuchi, Y; Shiozawa, K; Sumino, Y; Wakui, N; Watanabe, M | 1 |
Callaghan, C; Dash, S; Lee, BR; Liu, J; Maddox, M; Mandava, SH; Peralta, D; Tarr, MA | 1 |
Jakubowicz-Gil, J; Langner, E; Maciejczyk, A; Rzeski, W; Skalicka-Woźniak, K; Sumorek-Wiadro, J; Zając, A | 1 |
Asari, K; Takahashi, H | 1 |
Cai, W; Ghim, JL; Liu, S; Parvez, M; Shin, JG; Sun, H; Tang, Z; Wang, Z; Xiang, X | 1 |
Fan, K; Huang, H; Xie, ML; Xie, T; Zhao, Y; Zhu, ZY | 1 |
1 review(s) available for sorafenib and warfarin
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
8 other study(ies) available for sorafenib and warfarin
Article | Year |
---|---|
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Elevated International Normalized Ratio associated with concurrent use of sorafenib and warfarin.
Topics: Aged; Anticoagulants; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Interactions; Hemorrhage; Humans; International Normalized Ratio; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Warfarin | 2009 |
[Gastrointestinal hemorrhage associated with concurrent use of sorafenib and warfarin for hepatocellular carcinoma].
Topics: Anticoagulants; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tomography, X-Ray Computed; Warfarin | 2011 |
Combined Treatment of Tyrosine Kinase Inhibitor-Labeled Gold Nanorod Encapsulated Albumin With Laser Thermal Ablation in a Renal Cell Carcinoma Model.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Coumarins; Drug Compounding; Gold; Humans; Kidney Neoplasms; Lasers; Nanotubes; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Serum Albumin; Solubility; Sorafenib | 2016 |
Antiglioma Potential of Coumarins Combined with Sorafenib.
Topics: 4-Hydroxycoumarins; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Beclin-1; Caspase 3; Cell Line, Tumor; Cell Proliferation; Coumarins; Esculin; Gene Expression Regulation; Glioblastoma; Humans; Magnoliopsida; Necrosis; Phosphatidylinositol 3-Kinases; Plant Extracts; Proto-Oncogene Proteins c-bcl-2; raf Kinases; RNA, Small Interfering; Sorafenib; Umbelliferones | 2020 |
Proposal of a prediction model describing the metabolic interaction between warfarin and sorafenib using a population pharmacokinetic approach.
Topics: Anticoagulants; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Genotype; Humans; International Normalized Ratio; Sorafenib; Vitamin K Epoxide Reductases; Warfarin | 2021 |
A physiologically based pharmacokinetic/pharmacodynamic modeling approach for drug-drug interaction evaluation of warfarin enantiomers with sorafenib.
Topics: Anticoagulants; Blood Coagulation; Computer Simulation; Cytochrome P-450 CYP2C9; Dose-Response Relationship, Drug; Drug Interactions; Hemorrhage; Humans; International Normalized Ratio; Models, Biological; Models, Theoretical; Pharmacogenomic Testing; Risk Assessment; Sorafenib; Vitamin K Epoxide Reductases; Warfarin | 2021 |
Osthole Increases the Sensitivity of Liver Cancer to Sorafenib by Inhibiting Cholesterol Metabolism.
Topics: Animals; Cholesterol; Coumarins; Liver; Liver Neoplasms; Mice; Sorafenib; Sterol Regulatory Element Binding Protein 1; Sterol Regulatory Element Binding Protein 2 | 2022 |